Functional reprogramming of human prostate cancer to promote local attraction of effector CD8+T cells

Synergistic COX2 Induction by IFN  and TNF  Self-Limits Type-1 Immunity in the Human Tumor Microenvironment

(2016) J. L. Wong et al.   Cancer Immunology Research

Mesenchymal Stem/Stromal Cells Protect against Autoimmunity via CCL2-Dependent Recruitment of Myeloid-Derived Suppressor Cells

(2015) Hyun Ju Lee et al.   JOURNAL OF IMMUNOLOGY

Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy

(2015) Dongjun Peng et al.   NATURE

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

(2015) Christopher J. Sweeney et al.   NEW ENGLAND JOURNAL OF MEDICINE

CCL2 Promotes Colorectal Carcinogenesis by Enhancing Polymorphonuclear Myeloid-Derived Suppressor Cell Population and Function

(2015) Eunyoung Chun et al.   Cell Reports

Combination of IFNα and poly-I:C reprograms bladder cancer microenvironment for enhanced CTL attraction

(2015) Ravikumar Muthuswamy et al.   Journal for ImmunoTherapy of Cancer

Immune Infiltration and Prostate Cancer

(2015) Amy Strasner et al.   Frontiers in Oncology

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy

(2014) J. M. Taube et al.   CLINICAL CANCER RESEARCH

Activated Lymphocyte Recruitment Into the Tumor Microenvironment Following Preoperative Sipuleucel-T for Localized Prostate Cancer

(2014) Lawrence Fong et al.   JNCI-Journal of the National Cancer Institute

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Prostate Cancer Immunotherapy: Beyond Immunity to Curability

(2014) J. W. Simons   Cancer Immunology Research

NF- B Hyperactivation in Tumor Tissues Allows Tumor-Selective Reprogramming of the Chemokine Microenvironment to Enhance the Recruitment of Cytolytic T Effector Cells

(2012) R. Muthuswamy et al.   CANCER RESEARCH

Prostaglandin E2 Suppresses Poly I

(2012) Mayumi Ueta et al.   CORNEA

Prostaglandin E2 induces stromal cell-derived factor-1 expression in prostate stromal cells by activating protein kinase A and transcription factor Sp1

(2012) Yanfei Peng et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

PGE2-Induced CXCL12 Production and CXCR4 Expression Controls the Accumulation of Human MDSCs in Ovarian Cancer Environment

(2011) N. Obermajer et al.   CANCER RESEARCH

Prostate Cancer: Evolution or Revolution?

(2011) Eric J. Small et al.   JOURNAL OF CLINICAL ONCOLOGY

Tumor-Infiltrating CD8+ Lymphocytes Predict Clinical Outcome in Breast Cancer

(2011) Sahar M.A. Mahmoud et al.   JOURNAL OF CLINICAL ONCOLOGY

Regulation of Immune Responses by Prostaglandin E2

(2011) P. Kalinski   JOURNAL OF IMMUNOLOGY

Infiltration of tumour-associated macrophages in prostate biopsy specimens is predictive of disease progression after hormonal therapy for prostate cancer

(2010) Norio Nonomura et al.   BJU INTERNATIONAL

Androgen Deprivation Boosts Prostatic Infiltration of Cytotoxic and Regulatory T Lymphocytes and Has No Effect on Disease-Free Survival in Prostate Cancer Patients

(2010) Carlo Sorrentino et al.   CLINICAL CANCER RESEARCH

The biology of myeloid-derived suppressor cells: The blessing and the curse of morphological and functional heterogeneity

(2010) Je-In Youn et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

(2010) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

(2010) Philip W. Kantoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Regression of prostate tumors upon combination of hormone ablation therapy and celecoxib in vivo

(2010) Parisa Abedinpour et al.   PROSTATE

Chemokine Expression in Melanoma Metastases Associated with CD8+ T-Cell Recruitment

(2009) H. Harlin et al.   CANCER RESEARCH

CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis

(2009) Jian Zhang et al.   CYTOKINE & GROWTH FACTOR REVIEWS

Biomolecular Network Reconstruction Identifies T-Cell Homing Factors Associated With Survival in Colorectal Cancer

(2009) Bernhard Mlecnik et al.   GASTROENTEROLOGY

Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients

(2009) Philippe O. Gannon et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Cutting Edge: Tumor-Specific CD8+ T Cells Infiltrating Prostatic Tumors Are Induced to Become Suppressor Cells

(2009) K. A. Shafer-Weaver et al.   JOURNAL OF IMMUNOLOGY

High density of FOXP3-positive T cells infiltrating colorectal cancers with microsatellite instability

(2008) S Michel et al.   BRITISH JOURNAL OF CANCER

Prostaglandin E2 Regulates Tumor Angiogenesis in Prostate Cancer

(2008) S. Jain et al.   CANCER RESEARCH

Ability of Mature Dendritic Cells to Interact with Regulatory T Cells Is Imprinted during Maturation

(2008) R. Muthuswamy et al.   CANCER RESEARCH

Phenotypic Analysis of Prostate-Infiltrating Lymphocytes Reveals TH17 and Treg Skewing

(2008) K. S. Sfanos et al.   CLINICAL CANCER RESEARCH

Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue

(2008) N Chaput et al.   GUT

Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study

(2008) Dominik R. Berthold et al.   JOURNAL OF CLINICAL ONCOLOGY

Abundant expression of CXCL9 (MIG) by stromal cells that include dendritic cells and accumulation of CXCR3+T cells in lymphocyte-rich gastric carcinoma

(2008) H Ohtani et al.   JOURNAL OF PATHOLOGY